Ono Pharmaceutical Announces Changes in Investigational AIDS Drug Development Program.
As a result, GSK has decided to terminate Phase IIB studies in HIV-positive patients who have never taken any AIDS drug. Further, GSK has made some changes to the protocol for phase III clinical studies in HIV-positive patients who have been treated with AIDS drugs.
ONO-4128/873140 is a CCR5 receptor antagonist. Ono Pharmaceutical and GSK entered into a licensing agreement for the agent in December 2002.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Sep 27, 2005|
|Previous Article:||Dai Nippon Printing (DNP) Invests in US Molecular Imprint Venture Concern.|
|Next Article:||Matsushita Electric Works Develops Flexible Optoelectronic PCB; Protype at CEATEC Japan 2005.|